Global

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

No one thought Brexit would be easy and in the wake of last week's UK election the going has only gotten tougher. Leela Barham looks at the fallout from a life sciences perspective.

With the UK's General Election set for June 8, Leela Barham looks what the competing parties are promising for pharma and healthcare

Several interventions and developments across the continent likely to keep discussions around drug affordability on high burn.

Although the local pharma and biotech sectors in Taiwan have yet to emulate the success story of its semiconductor industry, companies in the life sciences have reached a solid level of maturity, notably driven by the substantial investments injected by Taiwan’s successive governments over the past two decades.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector.

Home to some of the world’s most important international health institutions and some big pharma players as well, Switzerland lays claim as a healthcare and life sciences powerhouse. Navigating its pharmaceutical market terrain, however, does not come without its challenges.

The external reference pricing circus has rolled back into town, promising another great European show. The fight-back comes via one of Europe's most obscure bodies, the European Integrated Price Information Database-better known as Euripid.

The Innovation Scorecard was developed to track compliance with NICE Technology Appraisals. Leela Barham reviews its latest update.